What we do
Orthros develops therapeutic products for OA based on Llama antibodies. Originally the focus was for 100% on therapeutics for humans, but now there is parallel development of therapeutics for humans and for companion animals [in particular dogs]
Orthros follows 2 strategies to develop place and time specific therapeutics. Both use injection with a carrier close to the tissue to be repaired.
By doing so the costs of these therapeutics will be less than 10% of conventional antibodies:
- Anchorbodies, bi-specific VHH of which one recognizes damaged tissue, and the other binds endogenous Growth Factors or other molecules involved in tissue repair [protected by patent];
- Sinks for undesirable molecules, by specific linking VHH or bi-heads to hydrogels that bind molecules like MMPs; ADAMTS, or inflammation stimulating molecules.
Beside these two groups of therapeutics, Orthros and QVQ are in a process to select VHH that can be used for pain treatment.